Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Addex - Caught on Camera

Why Did HC Wainwright Downgrade Addex Therapeutics

Last week, Addex Therapeutics Ltd (NASDAQ:ADXN) terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow rate of patient recruitment. Addex is suspending its financial guidance. Hence HC Wainwright downgraded its rating to Neutral from Buy without a price target, as dipraglurant…

Benzinga · Jun 23, 2022

The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jun 17, 2022

Why Shares Of Addex Therapeutics Are Falling Today

Shares of small-cap penny stock Addex Therapeutics Ltd. (NASDAQ: ADXN) are trading lower after the company terminated its Phase 2b/3 study of Dipraglurant for dyskinesia associated with Parkinson's disease due to slow recruitment. The company suspended its guidance amid the termination.

Benzinga · Jun 17, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Addex Stops Parkinson's-Associated Dyskinesia Trial - Read Here Why

Addex Therapeutics Ltd (NASDAQ:ADXN) has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients. Data readout from the trial was expected in 1H of 2023. The company attributes this to the consequences of COVID-19-related patient concerns about participation in studies, staffing…

Benzinga · Jun 17, 2022

Addex Expands Pipeline With Selective M4 PAM Program For Schizophrenia & Other Psychotic Disorders

Addex Therapeutics (NASDAQ: ADXN) has moved a selective and potent M4 muscarinic receptor positive allosteric modulator (PAM) program into lead optimization, with a

Benzinga · Apr 6, 2022

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

424,412 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.